International Liver Congress
International Liver Congress
Source/Disclosures
Source: Healio.com
Disclosures: Flamm reports doing research for and consulting with Merck, Gilead and AbbVie.
September 09, 2020
1 min watch
Save

VIDEO: ‘Promising’ treatment for alcoholic hepatitis in development

Source/Disclosures
Source: Healio.com
Disclosures: Flamm reports doing research for and consulting with Merck, Gilead and AbbVie.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video, Steven Flamm, MD, chief of the liver program at the Northwestern Feinberg School of Medicine, discusses a potential treatment for alcoholic hepatitis that is currently in development.

Although its been known for decades, there are no approved therapies for alcoholic hepatitis. Flamm said that 1-month mortality rates for patients with acute alcoholic hepatitis can be as high as 40%.

Flamm said one drug currently in development, DUR-928 (Durect), has demonstrated good tolerability in previous research. He said that research presented at The Digital International Liver Congress explored pharmacokinetics of the drug and identified appropriate dosing levels in a phase 2b trial.